NYSE - Delayed Quote USD

Medtronic plc (MDT)

Compare

88.35

+0.21

(+0.24%)

At close: 9 October at 4:00 pm GMT-4

89.27

+0.92

(+1.04%)

Pre-market: 5:30 am GMT-4

Key events

Advanced chart

Loading Chart for MDT

9/21 12:03 PM

DELL

Previous close 88.14
Open 87.96
Bid --
Ask --
Day's range 87.67 - 88.44
52-week range 68.84 - 91.49
Volume 2,676,207
Avg. Volume 6,345,487
Market cap (intra-day) 113.318B
Beta (5Y monthly) 0.85
PE ratio (TTM) 29.75
EPS (TTM) 2.97
Earnings date 19 Nov 2024
Forward dividend & yield 2.80 (3.17%)
Ex-dividend date 27 Sept 2024
1y target est 95.04

Medtronic plc develops, manufactures, and sells device-based medical therapies to healthcare systems, physicians, clinicians, and patients worldwide. The Cardiovascular Portfolio segment offers implantable cardiac pacemakers, cardioverter defibrillators, and cardiac resynchronization therapy devices; cardiac ablation products; insertable cardiac monitor systems; TYRX products; and remote monitoring and patient-centered software. It also provides aortic valves, surgical valve replacement and repair products, endovascular stent grafts and accessories, and transcatheter pulmonary valves; and percutaneous coronary intervention products, percutaneous angioplasty balloons, and other products. The Neuroscience Portfolio segment offers medical devices and implants, biologic solutions, spinal cord stimulation and brain modulation systems, implantable drug infusion systems, and interventional products, as well as nerve ablation system under the Accurian name. The segment offers its products for spinal surgeons, neurosurgeons, neurologists, pain management specialists, anesthesiologists, orthopedic surgeons, urologists, urogynecologists, and interventional radiologists, as well as ear, nose, and throat specialists; and energy surgical instruments. The Medical Surgical Portfolio segment offers surgical stapling devices, vessel sealing instruments, wound closure and electrosurgery products, AI-powered surgical video and analytics platform, robotic-assisted surgery products, hernia mechanical devices, mesh implants, gynecology products, gastrointestinal and hepatologic diagnostics and therapies, and therapies to treat other non-exclusive diseases and conditions; and patient monitoring and airway management products. The Diabetes Operating Unit segment provides insulin pumps and consumables, continuous glucose monitoring systems, and InPen, a smart insulin pen system. The company was founded in 1949 and is headquartered in Galway, Ireland.

www.medtronic.com

95,000